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Abstract
Introduction: Hyperhomocysteinaemia is an independent risk factor for premature atherosclerotic vascular disease and venous thrombo-
sis. Hypothyroidism is associated with mild hyperhomocysteinaemia. The aim of the present study was to assess plasma total homocyste-
ine (tHcy) and its determinants (folate, cobalamin) in hyperthyroid patients before and after treatment.
Material and methods: Thirty hyperthyroid and thirty healthy premenopausal women were studied. The hyperthyroid patients were
investigated in the untreated state and again after restoration of euthyroidism. The levels of homocysteine, folate, cobalamin, and thyroid
stimulating hormone (TSH), free thyroxine (fT4), free triiodothyronine (fT3), and renal function were measured before and after treatment.
Results: In hyperthyroidism, tHcy was lower than in the control group. The serum level of folate was higher and serum cobalamin was lower
in the hyperthyroid state. Following antithyroid drug therapy, tHcy significantly increased and folate decreased. The level of cobalamin
remained unchanged. Univariate analysis in the hyperthyroid group indicated that tHcy significantly negatively correlated only with fT3.
Conclusions: Lower homocysteine levels in hyperthyroid state can be explained by the influence of thyroid hormone. High level of folate
is only partially responsible for these changes. (Pol J Endocrinol 2009; 60 (6): 443–448)
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Streszczenie
Wstęp: Podwyższone stężenie we krwi homocysteiny jest niezależnym czynnikiem ryzyka przedwczesnej miażdżycy tętnic oraz zmian
zakrzepowo-zatorowych naczyń żylnych. Łagodną hiperhomocysteinemię obserwuje się u osób z niedoczynnością tarczycy. Celem pracy
była analiza osoczowych stężeń całkowitej homocysteiny (tHcy, total homocysteine), kwasu foliowego oraz witaminy B12 u chorych kobiet
z nadczynnością tarczycy przed i po leczeniu.
Materiał i metody: Badaniu poddano 30 pacjentek z nadczynnością tarczycy oraz grupę kontrolną 30 zdrowych premenopauzalnych
kobiet. Grupa z nadczynnością tarczycy badana była 2-krotnie, przed leczeniem oraz po uzyskaniu eutyreozy. Oznaczano stężenia osoczowe
homocysteiny, kwasu foliowego, witaminy B12 oraz tyreotropiny (TSH, thyroid stimulating hormone), wolnej tyroksyny (fT4) i wolnej trójjodo-
tyroniny (fT3).
Wyniki: W grupie z nadczynnością tarczycy stężenie tHcy było istotnie niższe w porównaniu z grupą kontrolną. Stężenie kwasu foliowego
było znamiennie wyższe, a witaminy B12 niższe w grupie kobiet z nadczynnością. Po leczeniu tyreostatykami stężenie tHcy istotnie wzro-
sło, a kwasu foliowego obniżyło się. Stężenie witaminy B12 pozostało niezmienione. Analiza jednoczynnikowa w grupie z nadczynnością
tarczycy wykazała, że stężenie tHcy istotnie ujemnie korelowało tylko ze stężeniem fT3.
Wnioski: Obniżone stężenie homocysteiny w nadczynności tarczycy może być wyjaśnione wpływem hormonów tarczycy. Wysokie
stężenia kwasu foliowego tylko częściowo odpowiadają za te zmiany. (Endokrynol Pol 2009; 60 (6): 443–448)
Słowa kluczowe: homocysteina, witamina B12, kwas foliowy, nadczynność tarczycy
Introduction
Hyperhomocysteinaemia has been identified as a pre-
valent and strong risk factor of cardiovascular occlusi-
ve disease and venous thromboembolism [1–4]. The
relationship between homocysteine and cardiovascu-
lar disease is dose dependent and independent of other
risk factors [5]. Starting at a plasma total homocysteine
(tHcy) concentration level of 10 µmol/L, the risk increases
linearly [6]. Elevated plasma tHcy level (> 12 µmol/L) is
found in 5–10% of the general population and in up to
40% of patients with vascular disease [7]. Hyperhomo-
cysteinaemia can induce damage of vascular cells di-
rectly (endothelial injury, smooth muscle hypertrophy,
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vascular vasomotor function damage) and throughout
the process of generating oxidative stress and oxida-
tion of LDL-Ch [8, 9]. Homocysteine (Hcy) induces pla-
telet aggregation and activity of factor V and XII, and
inhibits the following: anticoagulant activity, protein C,
and antithrombin III [10–12].
Homocysteine is a sulphur-containing amino acid
biosynthesized from methionine, an essential amino
acid. Homocysteine is an intermediate product in the
transfer of activated methyl groups from tetrahydrofo-
late to S-adenosylmethionine (the reversible remethy-
lation pathway). This reaction is catalyzed by the me-
thionine synthetase and requires vitamin B12 as a cofac-
tor and 5-methyloTHF from folate as a methyl donor.
Homocysteine can also be metabolized by irreversible
transsulfuration pathway and requires vitamin B6 as an
enzyme cofactor.
Age, gender, life style (coffee, alcohol), and very rare-
ly occurring enzyme function impairment have an im-
pact on Hcy metabolism [13–15]. Other factors influen-
cing plasma tHcy concentration are: vitamin deficiencies,
medicaments (methotrexate and other folate antagoni-
sts, oral contraceptives, antagonists of vitamin B12 and B6,
thiazides, fibrate), and diseases such as: renal failure,
hepatic insufficiency, pernicious anaemia, and cancers.
Several studies have demonstrated elevated levels
of tHcy in patients with hypothyroidism [16, 17]. Once
euthyroidism was achieved with L-thyroxine therapy,
tHcy after overnight fasting significantly decreased [18,
19]. In the opposite way: higher plasma tHcy level may
be responsible for premature atherosclerosis observed
in hypothyroid patients [20]. Even a mild variation of
the thyroid hormone (within the normal range) in pa-
tients with coronary artery disease may change the re-
sult of coronary angiography. Higher concentrations of
serum free thyroid hormone were associated with de-
creased severity of coronary atherosclerosis [21]. A few
studies indicated lower tHcy levels in the hyperthyro-
id state. The heterogeneity of the study population with
respect to gender, age, vitamin status, etc probably re-
duced the impact of this observation.
The aim of this study was to determine plasma tHcy
in recently diagnosed hyperthyroid women before and
after treatment and to evaluate the potential role of Hcy
determinants such as plasma levels of folate, vitamin
B12, and renal function.
Material and methods
Participants
Thirty female study participants were prospectively
recruited from subjects referred to our thyroid outpa-
tient clinic. These patients were between 19 and 52 years
of age (average age 37.3 ± 9.8 years). Inclusion criteria
were: a newly, non-treated hyperthyroidism and regular
menses. Diagnosis of hyperthyroidism was based on clini-
cal examination and basal serum TSH values < 0.3 mU/L
and fT4 > 24 pmol/L or fT3 > 5.3 pmol/L. The control
group consisted of 30 female healthy volunteers betwe-
en 20 and 44 years of age (average age 31.4 ± 7.7).
Exclusion criteria were: diseases and drugs (folate,
vitamin B12, and B6 antagonists, anticonvulsants, thiazi-
des, fibrate) that change plasma Hcy levels; pregnancy,
lactation, and taking oral contraception; clinical or hi-
story of arteriosclerotic disease; excess of alcohol and
coffee consumption and special restrictions of diet. The
study protocol was approved by the Regional Ethics
Committee. All participants gave their informed con-
sent to participate in this study.
Basic routine blood chemistry tests (including cre-
atinine concentration) were performed for each patient.
Serum TSH, fT4, fT3, vitamin B12, folate, and tHcy levels
were also measured. Second blood analysis was done
after obtaining euthyroid state, after more than 2–3 mon-
ths of treatment with thiamazol (Thyrozol Merck, Darm-
stadt, Germany) in individualized doses. Participants
were advised not to change their lifestyle.
Biochemical methods
After physical examination, body mass indexes (BMI)
were measured and blood samples were taken at 9:00
a.m. after overnight fasting. The plasma was separated
within 20 minutes by centrifugation at 3000 rpm for
5 minutes and stored at –20° C until time of analysis.
Serum fT4, fT3, and TSH levels were determined by
microparticle enzyme immunoassay (MEIA) obtained
from Abbott Laboratories (AxSYM analyzer). The nor-
mal range for fT4 was 9–24 pmol/L, for fT3 it was 2.2–
–5.3 pmol/L, and for TSH, 0.3–5.0 mU/L. Serum folic acid
was determined by MEIA assay (Abbott Laboratories) by
IMx analyzer. The reference range was: 2.9-18.7 ng/ml.
Vitamin B12 was determined by chemiluminescent mi-
croparticle immunoassay (CMIA) (Abbott Laboratories)
with Architect system — reference range 179–1162 pg/ml.
tHcy was determined by fluorescence polarization
immunoassay (FPIA); we used a reference range of:
< 12 µmol/L for healthy persons and < 10 µmol/L for
individuals with high cardiovascular risk [21, 22]. The
relative coefficient of variation of this assay varies be-
tween 1.4% and 5.2% and the correlation with standard
high performance liquid chromatography (HPLC) is
high (r = 0.989) [24].
Serum creatinine was measured by an automa-
ted enzymatic method, and creatinine clearance (Clcr)
was calculated using the Cockcroft-Gault formula: Ccr
(ml/min) = [(140–age (years)/72 × Ccr ] × weight (kg); for
women this value was multiplied by 0.85. This formula
has a significant correlation to GFR in the literature [25].
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Statistical analysis
The data of the hyperthyroid group (before and after tre-
atment) and the control group were determined using
Student´s paired t-test. In the case of non-Gaussian di-
stribution, the original data were transformed to attain
normal distribution. After transformation, all of these
variables had a normal distribution. Univariate relations
between tHcy and other variables are presented as Pear-
son rank correlations. To assess the simultaneous rela-
tion among the various predictors of tHcy, multiple line-
ar regression models were used. The analyses were per-
formed with log-tHcy as the dependent variable. We used
the statistical package Statistica 6.0 (StatSoft).
Results
Table I summarizes the clinical and laboratory data of
patients and of the control group. Women with hyper-
thyroidism had statistically significant lower TSH and
higher fT4 than the control group. Mean tHcy levels in
patients before treatment (8.20 ± 1.81 µmol/L) were
significantly lower than in the control group (10.81 ±
± 2.44 µmol/L, p < 0.001). In the patient group, a deficien-
cy of vitamin B12 was not observed, but the mean value
of vitamin B12 was significantly lower than in the control
group (344.86 ± 102.08 pg/ml v. 420.83 ± 142.07 pg/ml,
p = 0.023). No subject had evidence of folate deficien-
cy, although folate was significantly higher in women
with hyperthyroidism in comparison with the controls
(8.65 ± 2.55 v. 5.88 ± 3.09 ng/ml, p < 0.001).
After recovery of euthyroidism in fasting state,
tHcy significantly increased from 8.20 ± 1.81 to 9.64 ±
± 2.57 µmol/L (p=0.004), folate significantly decreased
from 8.65 ± 2.55 to 6.37 ± 1.94 pg/ml (p < 0.001), altho-
ugh vitamin B12 remained unchanged.
The mean levels of creatinine clearance were not si-
gnificantly lower in hyperthyroid patients v. Controls,
and  decreased significantly after treatment (Table II).
Table II. Characteristics the hyperthyroid group before and after treatment
Tabela II. Charakterystyka chorych z nadczynnością tarczycy przed i po leczeniu
Hyperthyroid Euthyroid p value
BMI [kg/m2] 22.34 ± 3.10 23.33 ± 3.17 < 0.001
TSH [mU/L] 0.004 ± 0.004 0.874 ± 1.524 < 0.001
fT4 [pmol/L] 52.49 ± 31.82 11.42 ± 5.37 < 0.001
fT3 [pmol/L] 17.23 ± 11.07 3.87 ± 1.46 < 0.001
tHcy [µmol/L] 8.20 ± 1.81 9.64 ± 2.57 0.004
Folic acid [ng/ml] 8.65 ± 2.55 6.37 ± 1.94 < 0.001
Vitamin B12 [pg/ml] 344.86 ± 102.08 336.8 ± 137.4 0.335
Clcr [ml/min] 112.8 ± 30.6 84.8 ± 20.9 < 0.001
Table I. Characteristics of the study group and control group
Tabela I. Charakterystyka grupy badanej i kontrolnej
Characteristics Study group Control group p value
Total 30 30 –
Age (year) 37.3 ± 9.8 31.4 ± 7.7 0.012
BMI [kg/m2] 22.34 ± 3.1 23.13 ± 5.54 0.517
Coffee [cup/d] 1.2 ± 1.0 2.0 ± 1.4 0.019
Cigarette [piece/d] 0.7 ± 1.7 0.2 ± 0.4 0.160
Multivitamin [% of people] 6.7% 33.3% 0.010
TSH [mU/L] 0.004 ± 0.004 1.32 ± 0.73 < 0.001
fT4 [pmol/L] 52.49 ± 31.82 15.61 ± 3.98 < 0.001
fT3 [pmol/L] 17.23 ± 11.07 no date no date
tHcy [µmol/L] 8.20 ± 1.81 10.81 ± 2.44 < 0.001
Folic acid [ng/ml] 8.65 ± 2.55 5.88 ± 3.09 < 0.001
Vitamin B12 [pg/ml] 344.86 ± 102.08 420.83 ± 142.07 0.023
Clcr [ml/min] 112.8 ± 30.6 113.1 ± 23.3 0.696
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In univariate analysis, decreased tHcy was signi-
ficantly associated with high fT3 levels (r = –0.28;
p = 0.037) (Table III).
In multivariate analysis, decreased fasting tHcy sta-
te was associated with low vitamin B12 levels (b = –0.29;
p = 0.042).
Discussion
In the present study, we found that women with hy-
perthyroidism had a significantly lower mean tHcy
2.6 µmol/L compared with the control group. Normali-
zation of thyroid hormone levels with antithyroid drug
treatment was associated with a significant tHcy incre-
ase. In univariate analysis, the serum levels of fT3 were
significant determinants of plasma tHcy. These obse-
rvations are consistent with the results of Demirbas et
al. [26]. They observed that tHcy levels were significan-
tly lower in patients with hyperthyroidism than in he-
althy subjects (11.5 ± 3.6 µmol/L v. 15.1 ± 4.5 µmol/L,
p < 0.05) and increased significantly after treatment.
However, no significant correlations were found in corre-
lation analysis. In the largest published study on plasma
tHcy and hyperthyroidism (182 patients), normalization
of thyroid status was associated with a significant incre-
ase of tHcy (8.3 v. 9.2 p < 0.005); in correlation analysis,
a significant correlation with fT4 was observed [27]. The
changes of plasma tHcy in relation to thyroid status may
be explained by the influence of thyroid hormones on
a variety of biochemical processes in Hcy metabolism,
distribution, or clearance [28]. Several experimental stu-
dies have shown that the activity of flavoprotein me-
thylene tetrahydrofolate reductase (MTHFR), the en-
zyme that participates in folate metabolism, is influen-
ced by thyroid status [29]. Hepatic activity of MTHFR is
increased in hyperthyroid state and reduced in hypo-
thyroid state. In the reaction catalysed by this enzyme,
the methyltetrahydrofolate is formed (it is a methyl
— donor in Hcy remethylation catalysed by the me-
thionine synthase). This mechanism could explain the
changes in plasma tHcy level observed in thyroid dys-
function and after treatment. The influence of thyroid
hormone on MTHFR occurs by the stimulating synthe-
sis of the coenzyme flavin adenine dinucleotide (FAD).
FAD protects the MTHFR from inactivation. We inve-
stigated the plasma concentration of vitamin B12 and folic
acid (both involved in the remethylation pathway). Vi-
tamin B12 acts as a cofactor for methionine synthase and
folate as a methyl donor in the remethylation of Hcy to
methionine. Vitamin deficiency leads to reduced reme-
thylation and elevated plasma tHcy. In our study none
of the patients had a vitamin deficiency. In the hyper-
thyroid group before treatment, the level of folate was
higher than in the control group and decreased after
treatment. This may be explained by the increased acti-
vity of MTHFR in hyperthyroid state. This enzyme pro-
duced higher levels of methyltetrahydrofolate — a form
marked in the laboratory tests. Ford et al. observed ele-
vated serum folate levels in hyperthyroidism [29]. This
finding is in agreement with the results of Nedrebo et
al. [27, 31] and Demirbas et al. [26]. Another study de-
monstrated higher folate levels in a hyperthyroid gro-
up compared to a hypothyroid group, a decrease after
treatment of hyperthyroid patients, and a positive cor-
relation between tHcy and folate level [19]. We did not
find any significant correlation between plasma tHcy
and folate in univariate analysis. Conversely, studies on
hypothyroid patients found lower folate levels [18, 32]
and concluded that tHcy in hypothyroidism is associa-
ted with an altered folate status. We did not observe
any correlation between tHcy and vitamin B12 in univa-
riate analysis. Pretreatment levels of vitamin B12 were
inconsiderably lower in hyperthyroid patients, but after
treatment were unchanged. Demirbas et al. [26], when
studying hyperthyroid patients, did not find any diffe-
rences in B12 levels between hyperthyroid and healthy
subjects both before and after antithyroid therapy. Ne-
drebo et al. observed a reduction in plasma vitamin B12
following antithyroid therapy [27]; however, in another
study they found no relation to thyroid status [31]. In
hypothyroid patients, others have demonstrated redu-
ced [33, 34] or unchanged levels of vitamin B12 [19, 35].
The following mechanism for alterations of tHcy le-
vels is the renal function. Thyroid hormones influence
renal blood flow, glomerular filtration rate (GFR), and
active tubular transport [36, 37], and are related to the
severity of thyroid dysfunction. Several studies have
demonstrated reduced serum creatinine levels and en-
Table III. Correlations between plasma tHcy and other
parameters in the hyperthyroid group in univariate analysis
Tabela III. Korelacje pomiędzy osoczowym stężeniem tHcy
i innymi parametrami w grupie z nadczynnością tarczycy
(analiza jednoczynnikowa)
Parameter ln (tHcy)
r p
Age (year) –0.07 0.674
BMI [kg/m2] 0.12 0.453
Ln (TSH) 0.04 0.799
Ln (fT4) –0.25 0.096
Ln (fT3) –0.28 0.037
Ln (folic acid) –0.27 0.081
Ln (Vit. B12) –0.27 0.079
Clcr –0.04 0.798
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hanced GFR in hyperthyroidism, and its normalisation
after achieving euthyreosis [38, 39]. Even a mild reduc-
tion in GFR leads to increased levels of Hcy. There are
reports of a positive correlation between tHcy and se-
rum creatinine concentrations [40]. The clearance of Hcy
plays a major role in kidney metabolism of this amino
acid, and renal excretion of Hcy is negligible [41]. Une-
xpectedly, in our study hyperthyroid patients had cre-
atinine clearance similar to the control group. After tre-
atment we observed its significant decrease. In univaria-
te analysis, this parameter was not correlated with tHcy.
The important elements of our findings are prospec-
tive, longitudinal design and homogeneous population.
We ruled out the other main factors associated with
hyperhomocysteinaemia. Our patients were young
women (mean age 37.3 + 9.8 yrs), with regular menses,
who led healthy lives, and were without other diseases.
In adults, tHcy is usually about 2 mmol/L higher in men
than in women. From puberty to old age, tHcy incre-
ases 3–5 µmol/L in both sexes. After menopause, tHcy
gradually rises and reaches the level of men. Sex-rela-
ted differences are explained by the effects of oestro-
gen status [42, 43]. Concentrations of tHcy are different
in the follicular and luteal phase of the menstrual cycle
[44, 45]. Therefore, the differences in menstrual status
may affect tHcy levels and obscure the results. In our
study we did not take into account the phase of the
cycle because hyperthyroidism can be the cause of the
anovulation.
In conclusion, our study confirms previous observa-
tions, showing that the hyperthyroid status is associa-
ted with decreased plasma tHcy concentrations. Free
triiodothyronine is an independent determinant of pla-
sma tHcy. Higher folate levels in hyperthyroidism only
partially explain the changes in tHcy.
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